DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced it has received the ENERGY
STAR® Partner of the Year Sustained Excellence Award for
2020, marking the seventh consecutive year it has earned ENERGY
STAR®'s highest honor. The U.S. Environmental
Protection Agency award recognizes Allergan for its continued
leadership in energy management and efficiency.
"Allergan is proud of its longstanding commitment to increasing
our energy efficiency and reducing our impact on the environment.
Four years ago, we set an aggressive goal to reduce our total
energy usage by 20 percent between 2015 and 2020 and today we are
well on our way to achieving that goal. We congratulate our global
colleagues for their tremendous efforts to support environmental
responsibility, which continue to be recognized year after year,"
said Wayne Swanton, Executive Vice President, Global
Operations at Allergan.
Prior to earning the ENERGY STAR® Sustained
Excellence distinction for the last seven years, Allergan was
recognized as an ENERGY STAR® Partner of the Year for
two consecutive years. Additionally, Allergan's manufacturing
facility in Waco, Texas was
recently named an ENERGY STAR® Certified Manufacturing
Plant for superior energy performance, a distinction earned only by
plants in the top 25 percent of energy performance in the United States. Allergan also achieved
ENERGY STAR® certification for a building located at its
Irvine, California
campus. Allergan has been an ENERGY
STAR® partner since 1996.
For a complete list of 2020 winners and more information about
ENERGY STAR's awards program, visit
energystar.gov/awardwinners.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
About ENERGY STAR
ENERGY STAR® is the government-backed symbol for
energy efficiency, providing simple, credible, and unbiased
information that consumers and businesses rely on to make
well-informed decisions. Thousands of industrial, commercial,
utility, state, and local organizations—including more than 40
percent of the Fortune 500 companies—rely on their partnership with
EPA to deliver cost-saving energy efficiency solutions. Since 1992,
ENERGY STAR and its thousands of partners helped American families
and businesses save more than 4 trillion kilowatt-hours of
electricity and achieve over 3.5 billion metric tons of greenhouse
gas reductions. In 2018 alone, ENERGY STAR and its partners helped
Americans avoid nearly $35 billion in
energy costs. More background information about ENERGY STAR can be
found at: energystar.gov/about and energystar.gov/numbers.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2019.
Except as expressly required by law, Allergan disclaims any intent
or obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7488
Media:
Lisa Brown
(862) 261-7320
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-earns-energy-star-partner-of-the-year--sustained-excellence-award-for-the-seventh-consecutive-year-301032547.html
SOURCE Allergan plc